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Introduction
By the end of 2012, more than 7.5 million of the estimated 23.5 
million people living with human immunodeficiency virus (HIV) 
in Africa were receiving treatment, compared to only 50 000 
people a decade before.1 The scale-up of treatment services in 
such a short period of time has been remarkable. Recent evidence 
suggests that HIV-attributable mortality has declined by more 
than 50% since antiretroviral therapy (ART) became available.2–8
Nonetheless, considerable concerns remain regarding 
high attrition rates throughout the continuum of care from 
HIV diagnosis, pre-ART care, timely initiation of ART and 
long-term retention in treatment.9 Various studies have ob-
served substantial drop-out of people living with HIV across 
this care cascade. A recent pooled analysis of 37 studies in 
sub-Saharan Africa indicates that among those knowing their 
status, only 57% completed ART eligibility assessment, 66% 
of those eligible initiated ART and 65% of those initiating 
treatment were retained on ART.10
The network for analysing longitudinal population-based data 
on HIV in Africa (ALPHA) is investigating the extent of declines 
in HIV-related adult mortality attributable to treatment and the 
distribution of deaths at each stage of the diagnosis-to-treatment 
cascade.11–14 The network collects community-based data from 10 
health and demographic surveillance sites in six countries with 
generalized epidemics – Kenya, Malawi, South Africa, Uganda, the 
United Republic of Tanzania and Zimbabwe. Table 1 identifies the 
ALPHA network sites and provides contextual information on the 
epidemic and treatment programme in each country.
To interpret site- and country-specific differences in 
mortality rates across the diagnosis-to-treatment cascade, we 
analysed national HIV policies. It is helpful for the agencies 
that define programme priorities and analyse differences in 
outcomes to understand the incentives and barriers to ac-
cessing – and remaining on – ART in different contexts. Our 
analysis focuses on the policy response to the HIV epidemic. 
We have not investigated the sociocultural barriers within 
communities that influence access to services in different sites.
Objective To compare national human immunodeficiency virus (HIV) policies influencing access to HIV testing and treatment services in 
six sub-Saharan African countries.
Methods We reviewed HIV policies as part of a multi-country study on adult mortality in sub-Saharan Africa. A policy extraction tool was 
developed and used to review national HIV policy documents and guidelines published in Kenya, Malawi, South Africa, Uganda, the United 
Republic of Tanzania and Zimbabwe between 2003 and 2013. Key informant interviews helped to fill gaps in findings. National policies 
were categorized according to whether they explicitly or implicitly adhered to 54 policy indicators, identified through literature and expert 
reviews. We also compared the national policies with World Health Organization (WHO) guidance.
Findings There was wide variation in policies between countries; each country was progressive in some areas and not in others. Malawi 
was particularly advanced in promoting rapid initiation of antiretroviral therapy. However, no country had a consistently enabling policy 
context expected to increase access to care and prevent attrition. Countries went beyond WHO guidance in certain areas and key informants 
reported that practice often surpassed policy.
Conclusion Evaluating the impact of policy differences on access to care and health outcomes among people living with HIV is challenging. 
Certain policies will exert more influence than others and official policies are not always implemented. Future research should assess the 
extent of policy implementation and link these findings with HIV outcomes.
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Table 1. Characteristics of the HIV epidemic in the six African countries9, 15-24
Characteristic Kenya Malawi South Africa Uganda United Republic 
of Tanzania
Zimbabwe
Demographic surveillance 
site(s)
Nairobi and 
Kisumu
Karonga Agincourt and 
UmKhanyakude
Masaka and 
Rakai
Ifakara and 
Kisesa
Manicaland
Adult HIV prevalence in 
201315
6.0 10.3 19.1 7.4 5.0 15.0
Year of public sector ART 
introduction
2006 2004 2003/2004 2004 2003/2004 2004
Adult ART coverage in 
2013a % (range)15
42 (39–46) 51 (48–53) 42 (40–43) 40 (38–43) 41 (38–44) 51 (49–53)
PMTCT coverage in 2013b 
% (range)15
63 (55–72) 79 (71–88) 90 (83– 95) 75 (68–85) 73 (65–83) 78 (70–87)
Adults knowing their HIV 
statusc %
36–5616,17 2818 36–5519 5620 54.521 46.522
Pregnant women knowing 
their HIV status in 201323
88 76 93 > 95 70 > 95
Donor funding as a 
proportion of total HIV/
AIDS budget in 20139
75–100 75–100 0–24 75–100 50–74 75–100
Doctors per 100 000 
people24
1.8 0.2 7.6 0.1 1.2 0.6
AIDS: acquired immunodeficiency syndrome; ART: antiretroviral therapy; HIV: human immunodeficiency virus; PMTCT: prevention of mother-to-child transmission.
a  Defined as the percentage of adults (15 years and older) living with HIV and receiving ART.
b  Defined as the estimated percentage of pregnant women living with HIV who received antiretroviral medicines for PMTCT.
c  Defined as testing at least once in the last 12 months and receiving results. Note that dates of studies vary.
Fig. 1. Conceptual framework of HIV policy and service factors influencing HIV-related adult mortality
Service access and coverage
• Costs of services
• Provider-initiated testing and 
counselling
• Services for high-risk groups
• Parental consent for youth
• Task-shifting for initiation
• Treatment options for opportunistic 
infections
• Outreach programmes
Quality-of-care
• Provider training
• Quality review/audit
• Confidentiality
• Record keeping
• Guideline availability
• Patient load
• Doctor/patient ratio
• Staff turnover
• Drug stockouts
• Limit on counselling sessions for 
HIV testers
• Stigmatization by health workers
Coordination of care and 
patient tracking
• Repeat testing
• Referral mechanisms
• Coordinated care
• Integration of services
• Pre ART monitoring
• Access to ART drugs (incl. refill 
intervals, collection options)
• Patient monitoring
• Patient tracing
Support to PLHIV
• Pre-/post-test counselling
• Couple counselling
• Adherence support
• Nutritional support
• Peer support groups
• Home-based care
Medical management
• Initiation criteria/theresholds/
timing (incl. in pregnancy, when 
infected with tuberculosis)
• Counselling requirements
• Laboratory tests
• Tuberculosis screening
• Prophylactic treatments
• ART regimen options
• Drug and equipment availability
National policy enviroment
Politics, laws and criminal justice system, regulatory frameworks, programme financing, decentralization, age of ART programme, donors, implementers
Policy Retention on ART
Treated with ART
Accessed care (pre-ART or ART eligibility assessment)
Diagnosed through HIV testing and counselling
Practice
ART: antiretroviral therapy; HIV: human immunodeficiency virus. PLHIV: people living with HIV.
Note: Factors in italics are only measurable and comparable through facility-based research and are not included in this review.
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Methods
A conceptual framework was developed, 
identifying key HIV policy and program-
matic factors that may influence HIV-
related adult mortality (Fig. 1). These 
factors were derived from a review of the 
literature (including a recent systematic 
review on health sector interventions to 
ensure a continuum of care),10 an initial 
review of World Health Organization 
(WHO) guidelines and expert review 
of indicators by 28 HIV researchers and 
clinicians. Through the literature review 
and preliminary analysis of ALPHA net-
work mortality data, we identified three 
attrition points to inform the structure 
of our policy review: (i) access to HIV 
testing and counselling; (ii) access to HIV 
care and treatment (including assessment 
of eligibility for treatment initiation and 
initiation itself); and (iii) retention on 
ART. Across these three attrition points 
(diagnosis, HIV care and retention), 
relevant factors fell into the following 
five areas: (i) service access and coverage; 
(ii) quality of care; (iii) coordination of 
care and patient tracking; (iv) medical 
management; and (v) support to people 
living with HIV.
A policy extraction tool was devel-
oped to facilitate the indicator review 
(available from the author). Documents 
were searched online through ministry 
of health and national HIV organiza-
tion websites and/or retrieved in person 
from official offices and libraries, using 
the following inclusion criteria: (i) na-
tionally relevant (not clinic- or district-
specific); (ii) containing programmatic 
or clinical guidance on one of the three 
key adult HIV services: HIV testing 
and counselling, prevention of mother-
to-child transmission (PMTCT) or 
HIV care and treatment; (iii) published 
between January 2003 and June 2013. 
Documents likely to fit these three cri-
teria were considered, including policy 
statements, clinical guidelines, training 
manuals, strategies, indicator guides 
and parliamentary acts. Guideline docu-
ments produced by WHO relevant to 
criteria (ii) and (iii) were also included.
The policy extraction tool was used 
to collect information on policy content, 
source, year and policy changes over 
time. Country teams completed gaps in 
data collection using unstructured in-
formal interviews with key informants. 
Informants were either regional or na-
tional policy-makers, researchers or cli-
nicians involved in policy development.
We summarized key policies judged 
most likely to affect access to HIV test-
ing, access to HIV care and treatment 
and retention on ART. For each indica-
tor, each country’s policy was catego-
rized into one of the following: (i) has 
explicit policy; (ii) has implicit policy or 
policy has caveats or exceptions; (iii) is 
unclear whether policy exists or policy 
conflicts with other policies; or (iv) does 
not have policy. We also assessed 
whether the policy was consistent with 
WHO guidance or a country standard 
that went beyond such guidance.
Results
A total of 120 policy documents with 
guidance relevant to the indicators were 
identified and reviewed; references are 
available from the author.
Access to testing
Fig. 2 summarizes policies influencing 
access to HIV testing. Policies in the 
six countries were generally consistent 
and explicitly or partially adhered to the 
policy indicators, including provision 
of free testing services and provider-
initiated testing and counselling. Malawi 
was the only country with no policy tar-
geting testing among high-risk groups; 
while Uganda and the United Republic 
of Tanzania did not define the high-risk 
groups. Only South Africa and Uganda 
had explicit policies enabling minors to 
access testing without parental consent.
Indicators related to quality of care 
were more variable. Anonymous HIV 
testing was guaranteed only in South 
Africa and Zimbabwe, whereas in Ke-
nya, Uganda and the United Republic 
of Tanzania names could be recorded 
in registers to facilitate patient manage-
ment. Various WHO documents empha-
sized confidentiality and protection from 
discrimination, but did not offer explicit 
guidance on maintaining anonymity. 
Only Kenya and the United Republic of 
Tanzania had policies limiting the num-
ber of testing sessions that counsellors 
can perform per day. While all countries 
stipulated the need for periodic refresher 
training for counsellors and quality con-
trol checks at sites, they varied in stated 
frequency, with the United Republic of 
Tanzania and Zimbabwe most explicit 
about how often retraining is required.
Policies influencing coordination 
of care and patient tracking were more 
ambiguous in the United Republic of 
Tanzania where there was no clear policy 
on repeat testing intervals for negatives 
or on repeat testing during pregnancy, 
labour or after delivery. Malawi was 
also ambiguous in this area, with repeat 
testing for negatives advised every 6–12 
months for high-risk individuals and no 
explicit policy on repeat testing during 
pregnancy.
Regarding patient support, Malawi, 
South Africa and Uganda also stipulated 
that pretest HIV counselling be con-
ducted either individually or in groups; 
others recommended at least one in-
dividual session. While all countries 
promoted couple counselling, this was 
not explicit in WHO guidance.
Access to care and treatment
Fig. 3 summarizes policies influencing 
access to care and treatment services, 
which varied more across countries. 
Free public sector access to PMTCT and 
ART was guaranteed everywhere, either 
explicitly in HIV policies or national 
health policies or implied in the national 
constitution, although WHO documents 
only implied free public sector access 
through promotion of universal access 
to HIV services. All countries promoted 
PMTCT availability within antenatal 
care and all allowed task-shifting of ART 
initiation to clinical officers, medical as-
sistants or nurses (albeit with important 
variations in year of policy formulation, 
with Kenya, Malawi and the United Re-
public of Tanzania allowing task shifting 
as early as 2004/2005). Only Malawi and 
Uganda had explicit policies stating that 
all sites providing ART should also be 
able to initiate ART.
All countries had explicit policies 
on the need for CD4+ T-lymphocyte 
(CD4+ cells) testing at least every six 
months in the pre-ART phase and all 
recorded pre-ART visits in patient reg-
isters or forms. Only Kenya, Uganda and 
the United Republic of Tanzania had 
explicit policies on patient follow-up to 
ensure registration at treatment sites. 
All countries except Zimbabwe stipu-
lated the need for PMTCT-ART referral, 
but only South Africa and the United 
Republic of Tanzania indicated when 
this referral should occur (six weeks 
after birth). Service integration between 
maternal and child health and ART was 
encouraged explicitly in Kenya, Malawi, 
Uganda and Zimbabwe.
Most countries adhered to WHO’s 
2010 Option B regimen for PMTCT 
(provision of triple drug therapy to the 
mother during pregnancy until delivery 
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or cessation of breastfeeding), except the 
United Republic of Tanzania which still 
adhered to WHO’s Option A regimen 
at the time of the review (single dose 
drug therapy with zidovudine [AZT] 
during pregnancy, triple therapy at 
onset of labour using nevirapine, AZT 
and lamivudine [3TC], followed by dual 
drug therapy for seven days postpartum 
with AZT and 3TC). Malawi was the 
only country to have explicitly adopted 
WHO’s Option B+ regimen (initiation 
of life-long triple ART therapy during 
pregnancy) for all women in 2011, which 
was earlier than WHO guidance. Roll-
out of Option B+ in Kenya and Uganda 
was dependent on the capacity of the 
health facility to initiate triple therapy.
Most countries had explicit policies 
allowing all people co-infected with HIV 
and tuberculosis to initiate ART, but dif-
fered markedly in their year of uptake 
of this policy, ranging from 2004 in Ma-
lawi, to 2013 in South Africa. Country 
guidance varied on tuberculosis and 
HIV treatment initiation: Malawi and 
Uganda stated that co-infected patients 
must initiate ART on the same day or 
within two weeks of starting tuberculo-
sis treatment (going beyond WHO guid-
ance of within eight weeks); while Kenya 
and the United Republic of Tanzania 
stated that treatment should preferably 
Fig. 2. WHO guidance and policies in six African countries influencing access to HIV testing, 2003 to mid-2013 25–56
Policy WHO guidance Kenya Malawi South Africa Uganda United Republic 
of Tanzania
Zimbabwe
Service coverage and access
Free testing at public facilities 2003
Implied25
200626 200427 201028 200529 200530 200731
PITC is standard for all clients including 
at ANC
200432 200833 200634 201035 201036 200737 2005 (ANC)38
2007 (others)39
Testing targeted at high risk groups 
(e.g. sex workers, men who have sex 
with men, injecting drug users)
200432 201040 201035 201036
Groups not defined. 
Some groups not 
legally recognized
200530
Implied. Target all, 
including vulnerable 
populations
200538
Parental consent not required for youth 
testing (<18 years)
200741 200833
If symptomatic, 
pregnant, married, 
parent, risky 
behaviours
200942
Parents/guardian 
should know for 
youth < 13 years
200543 201036 200737
Required for < 16 
years. Mature minors 
(married, pregnant 
or parents) can give 
own consent
200538
Required for < 16 
years. Mature 
minors (married, 
pregnant or 
parents) can give 
own consent
Quality of care
Anonymous HIV testing 200634
Names in other 
registers (e.g. ANC)
201035 200538
Maximum of 15 clients/day per 
counsellor
201144 Max 11–15, stressed 
in training of 
counsellorsa
Periodic refresher training for 
counsellors required
2001 onwards (all 
testing guidelines).
No frequency
201045
No frequency
200942
No frequency
201035
No frequency
200529
No frequency
200530
At least every year
200538
At least every year
Periodic quality control checks at 
testing sites required
200546
No frequency
201047
Twice a year 
(national)
200942
Quarterly for 
laboratory
201035
No frequency
200529
Quarterly
200530
Periodically; quarterly 
for laboratory
200538
At least every year
Coordination of care 
and patient tracking
Negatives retested 
every 6–12 months
200741 201048 200942
Every 6–12 months 
for high-risk 
individuals
201035 200529 Not written policy, 
but practice
200538
Repeat testing in the 3rd trimester of 
pregnancy (if previously tested negative)
201049 201050 200451
Implied
201052 201153 Repeat after window 
period
200739
Testing repeated during labour or after 
delivery if no prior test
201049 201050 Breastfeeding 
mothers offered 
routine testing every 
3 months
201052 201153 200739
Support to people 
living with HIV
Individual as well as group pre-test 
counselling recommended
200354 200833 200634
Individual or group
201035
Individual or group
200529
Individual or group
200530 200538
Couple counselling encouraged 200455 200833 200634 201035 200556 200530 200538
Has explicit policy Does not have policyHas implicit policy, or policy has caveats or exceptions Is unclear whether policy exists, or policy conflicts with other policies
ANC: antenatal care; HIV: human immunodeficiency virus; PITC: provider-initiated testing and counselling for HIV; WHO: World Health Organization.
a  Information from key informant interview.
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Fig. 3. WHO guidance and policies in six African countries influencing access to HIV care and treatment, 2003 to mid-2013 26,29,31,34,42,45,52–
55,57–84
Policy WHO guidance Kenya Malawi South Africa Uganda United Republic 
of Tanzania
Zimbabwe
Service coverage and access
Free PMTCT at public facilities Universal access 200626 2004a 199657
Implied in the 
constitution
201158 200759 200731
Free ART at public facilities Universal access 201160 200461 201062 201158 200759 200731
PMTCT available at all ANC facilities 201063 201264 2004a 201052 201153 201265
Implied
201166
Clinical officers, medical assistants 
and/or nurses initiate ART
200567 200468 201062 201158 200569 201070
Multitasking and 
task-shifting
All sites providing ART also initiate ART 200434 Not in policy, but 
practice
201158
Coordination of care and 
patient tracking 
HIV-positive clients followed-up to 
ensure registration at treatment site
200455 201045 No clear follow-up No clear follow-up 200529 201071
Clear guidance on when HIV-positive 
pregnant women referred to ART clinic
200671 201264
After delivery
2012
No specified time of 
referrala
201052
6 weeks after birth
201153
No specified time 
of referral
201265
Day 42 after birth
MCH and ART integration for mother 
and child encouraged
200672
Implied
201064 201173 201052
ART for mother not 
specified
201153 201070
6 monthly CD4 testing in pre-ART with 
CD4 count < 500 cells/µL
201160
Earlier if CD4 close to 
350 cells/µL
201173
Every 3 months
201062
Every 6 months
200374
Every 6 months
200569
Every 6 months
201070
Every 6 months
Pre-ART visits recorded 
(registers or forms)
Left to country 201160 201173 a 200975 200976 201077
Medical management 
WHO Option B ARV prophylaxis and 
ART regimen is the standard
201063 201264 201173
(Extended to B+)
201052 201153 201166
WHO Option B+ is the standard (all 
HIV-positive pregnant women initiate 
life-long ART)
201278 201264
Sites with capacity 
to initiate
201173 201153
At Level III and 
selected Level II 
health centres
All patients with tuberculosis eligible 
for ART initiation
200979 200780 200442,81 201382
Previously only 
MDR/XDR 
tuberculosis
201153 201283 201070
Once stabilized on 
tuberculosis 
treatment
Coinfected tuberculosis/HIV should 
initiate ART on the same day or within 
2 weeks of starting tuberculosis 
treatment
201384
As soon as possible 
within 8 weeks
201160
Within the initial 
2–8 weeks
201173 201382 201153 201283
As soon as possible, 
within 2 weeks 
preferably
Initiate ART at WHO stage 3/4; or 1/2 
with CD4 count ≤ 350 cells/µL
200979 201160 201173 201382 201153 201283 201070
Initiate ART within 7 days of ART 
eligibility
200567 201173 201382
for patients with 
urgent need
As soon as 
possible
Laboratory tests not required to start 
ART (e.g. FBC, LFTS/RFTS)
Strongly 
recommended
200567
Tests are desirable
2004a 201382 201158
At the earliest 
opportunity
Adherence counselling not compulsory 
before ART initiation
Strongly 
recommended
201173
Pregnant women 
allowed counselling 
later
201382
Has explicit policy Does not have policyHas implicit policy, or policy has caveats or exceptions Is unclear whether policy exists, or policy conflicts with other policies
ANC: antenatal care; ART: antiretroviral therapy; ARV: antiretroviral; CD4: cluster of differentiation 4; FBC: full blood count; HIV: human immunodeficiency virus; 
LFTS/RFTS: liver function/renal function tests; MCH: maternal and child health; MDR/XDR: multi-drug resistant/extensively-drug resistant; PMTCT: prevention of 
mother-to-child transmission; WHO: World Health Organization.
a  Information from key informant interview.
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be initiated within two weeks. While all 
countries shared the standard ART ini-
tiation criteria, only Kenya and Malawi 
stipulated explicitly that ART should 
be initiated within seven days of being 
found eligible for treatment. Malawi 
and South Africa also had more liberal 
policies allowing ART initiation with 
minimum requirements for tests and 
counselling. Malawi has not required 
laboratory tests for initiation since the 
beginning of the treatment programme 
(2004). South Africa brought in this 
change in 2013 and stated that adher-
ence counselling should not be compul-
sory before initiation.
Retention on ART
Fig. 4 summarizes policies influencing 
retention on ART. Stipulating that ART 
clinics include a doctor or clinical officer 
could be a barrier to access in resource-
constrained contexts. This requirement 
is still applied in Kenya, Malawi, the 
United Republic of Tanzania and Zim-
babwe (even though task-shifting for 
initiation occurred). Quality indicators 
also varied, with staff retraining and 
quality control intervals varying or not 
made explicit; for example no qual-
ity control was required after initial 
accreditation in South Africa, versus 
quarterly checks in Malawi, Uganda and 
the United Republic of Tanzania.
There were also important differ-
ences in coordination of care and patient 
tracking. Since the beginning of the 
treatment programme, Malawi did not 
promote routine CD4 monitoring, un-
like all other countries where yearly or 
six-monthly monitoring was standard. 
While most countries advised that 
stable patients receive a three-month 
supply of drugs, two months of supplies 
were stipulated in the United Republic 
of Tanzania and one month in South 
Africa. All countries promoted regular 
pill counts, but only South Africa and 
Zimbabwe had explicit policies on home 
visits following signs of poor adherence 
– others recommended home visits or 
telephone contact following missed 
appointments. Only Kenya explicitly 
recommended daily register reviews to 
identify missed appointments. Defini-
tions of missed appointments and loss 
to follow-up varied: Zimbabwe was most 
reactive with a missed appointment 
defined as a one-week delay, followed 
by Malawi where a two-week absence 
triggered action. Most countries defined 
loss to follow-up or defaulting as no at-
tendance within 90 days of the last visit, 
but the number of days was not defined 
in Malawi and was unclear in South 
Africa. Malawi, Uganda and the United 
Republic of Tanzania also allowed drug 
collection by designees (treatment part-
ners/guardians).
Support to those on ART varied. All 
countries explicitly or implicitly recom-
mended individual adherence counsel-
ling, but Malawi and Uganda did not 
stipulate referral to peer-support. Kenya 
and Uganda provided nutritional sup-
port to ART patients; Malawi stopped 
this in adults due to lack of evidence. 
Only South Africa, the United Republic 
of Tanzania and Zimbabwe routinely 
referred all ART patients to home-based 
care programmes.
All sites recommended routine 
screening for tuberculosis, but Zimba-
bwe did not routinely provide isoniazid 
preventive therapy for tuberculosis pre-
vention. All countries except Zimbabwe 
recommended at least four first-line ART 
regimen choices to patients, but not all 
complied with WHO’s 2010 recommend-
ed first line standard therapy (tenofovir, 
3TC and nevirapine/efavirenz). Zimba-
bwe was the first to introduce WHO’s 
recommended regimen in 2010. All coun-
tries except Malawi had clear criteria for 
switching to efavirenz-based regimens for 
patients who develop tuberculosis.
Discussion
Here we demonstrate wide variation 
in national HIV policies influencing 
service access and attrition through 
the diagnosis-to-treatment cascade 
across six countries with generalized 
HIV epidemics. Given that African 
countries usually adopt guidance from 
WHO, such a degree of policy variation 
is surprising.
Several indicators were consistent 
across all countries, but for many in-
dicators, countries were progressive in 
selected areas and no country stood out 
as having a consistently enabling policy 
context that would have a decisive im-
pact on service access and attrition. In 
Malawi, for example, policies designed 
to facilitate access to care (such as no 
requirements for routine CD4 test-
ing, early adoption of the Option B+ 
PMTCT regimen, rapid ART initiation 
for those eligible), contrasted with cer-
tain policy gaps (such as targeted test-
ing for high-risk groups, repeat testing 
during labour/after delivery, referral 
to peer support or home-based care 
for patients on ART). South Africa is 
another case where policies aiming to 
enhance access in some areas contrasted 
with policy gaps in others. South Africa 
had policies on anonymous HIV test-
ing, home visits following signs of poor 
adherence and few barriers to starting 
ART (no required laboratory tests, 
adherence counselling, or physician 
presence in ART clinics), but lacked 
policies on quality control for ART, pro-
vision of three-monthly ART supplies, 
guidance on missed appointments or 
loss to follow-up and compliance with 
WHO first-line regimen standards. In 
the United Republic of Tanzania, an 
enabling policy environment for reten-
tion of patients in care and treatment 
contrasted with the slow adoption of 
WHO Option B+ and ART regimens 
containing tenofovir (both subsequently 
adopted in September 2013), as well as 
weaknesses in repeat testing intervals.
There were also important differ-
ences in the timing of policy implementa-
tion in some indicators. Malawi adopted 
Option B+ in 2011 (before WHO guid-
ance) and has not required laboratory 
tests for ART initiation since 2004 (versus 
South Africa, which made this change in 
2013). Policies to trace missed appoint-
ments with home visits or phone contacts 
vary in dates of implementation from 
2004–2005 in Malawi and the United 
Republic of Tanzania, to 2011 in Kenya. 
While countries often lagged behind 
WHO in national policy adoption, in 
some instances countries went beyond 
WHO standards; notable examples in-
cluded policies related to pre-ART-CD4 
monitoring intervals, rapid initiation 
of ART, task-shifting for ART initia-
tion, drug resupply intervals, pill count 
recommendations, drug collection by 
designees, referral to peer support and 
home-based care. The fact that WHO had 
no explicit guidance on such topics may 
contribute to the differences in adoption 
of policies across countries.
Policies are likely to differ in their 
potential impact on service access and at-
trition. We are unable to judge, therefore, 
how policy differences are likely to influ-
ence mortality. There seems to be little 
correlation between policy profile and 
service coverage (Table 1). Our analysis 
did not attempt to weight policies – as 
this is likely to be highly subjective. One 
might expect that policies on patient 
coordination and tracking (e.g. pre-ART 
monitoring, timely initiation of ART 
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Fig. 4. WHO guidance and policies in six African countries influencing retention on ART, 2003–mid-2013 36,46,53,56,58,60,62,67,69,70,73,76,81–96
Policy WHO guidance Kenya Malawi South Africa Uganda United Republic 
of Tanzania
Zimbabwe
Service coverage and access
ART clinic staffing does not have to 
include doctor or clinical officer
200885 a 201158
Quality of care 
Periodic refresher training for ART 
staff required
201086 200987
Implied
200636
Every year
No frequencya 200356
No frequency
200569
Periodically
201070
No frequency
Period quality control checks at ART 
clinics required
201086 201160
No frequency
Every quartera 200356
Quarterly
201283
Quarterly supportive 
supervision
201070
No frequency
Coordination of care and 
patient tracking 
Routine 6 monthly CD4 count 
monitoring on ART
Not a prerequisite 200567 201382
Yearly
200356 200569 201070
3 monthly drug supplies once 
stable on ART
201160 201173 Monthly 201158 201283
For 2 months or more
201070
Pill counts at every visit 200567 200381 201062  No frequency 200356 200976 201070
Home visits following signs of poor 
adherence
201062 200888
Not part of Ministry 
of Health structure 
at facility level
Home-based care 
services include such 
visitsa
201070
Missed appointment defined when 
1 week late
201173
From 2 weeks
Not clear; 1 day 
common practicea
200689
Home visit or telephone contact for 
missed visits
201384 201160 201173 201062 200888 200569 200990
Daily review of missed 
appointment registers
Patient scheduling 
system may assist
201160 201173
Regularly reviewed
Not clear policy; 
common practicea
200888
Implied
200976
Implied 
Lost to follow up defined with no 
attendance for at least 90 days
200646 201091 No. days absence 
not defined
Not clear policy
1 month common 
practicea
201158 200976 201292
Drugs can be collected by a 
designee
2004a Not more than 
twicea
200569
HIV and tuberculosis services should 
be integrated within 1 facility
201193 200567 2011
Encouraged
201382 200694 200976
At least screening
201070
Within health system
Support to people living 
with HIV
At least 1 adherence counselling 
conducted individually
200567 201173 201062 200356 200976
Implied
201070
All patients on ART referred to peer 
support groups
201160 201062 Peer support 
recommended
201283 201070
Nutritional supplements for 
malnourished patients
200695 200567 Adult programme 
stopped. Now, only 
for children
200356 201283
Therapeutic foods
All patients on ART referred to 
home-based care
201062 200996
Not all
200976 200990
Medical management
IPT for all HIV patients without 
active tuberculosis
201093 201160 201173 201062 201158 201283
Tuberculosis screening at every 
pre-ART and ART visit
201093 200567 201173 201062 200356 200976 201070
WHO first line ART as standard 201086 201160 d4T/3TC/NVP
Plan to switch
d4T/3TC/NVP 201153 AZT+3TC+EFV 201070
At least 4 first line regimen choices 
in national programme
200695 201160 201173 201382 201153 200569
Patients on ART who develop 
tuberculosis switch to EFV-based 
regimen
200695 201160 Unclear First line therapy 
includes EFV
200356 200569 201165
Has explicit policy Does not have policyHas implicit policy, or policy has caveats or exceptions Is unclear whether policy exists, or policy conflicts with other policies
3TC: lamivudine; ART: antiretroviral therapy; AZT: zidovudine; CD4: cluster of differentiation 4; d4T: stavudine; EFV: efavirenz; HIV: human immunodeficiency virus; 
IPT: isoniazid preventive therapy; NVP: nevirapine; WHO: World Health Organization.
a  Information from key informant interview.
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and adherence monitoring) have greater 
impact than policies on quality of care 
(e.g. staff training or quality audits). The 
relative emphasis on different policies 
also varied; some indicators were only 
mentioned once in one document, while 
others were core tenets of HIV service 
delivery and repeatedly mentioned.
We attempted to frame all policies 
as designed to increase service access 
and reduce attrition, but the direction 
of effect was not always clear-cut. For 
example, anonymous testing may pro-
mote access to diagnosis by reducing 
stigma, but may hamper linkage to care. 
Group pretest counselling may facilitate 
test access but have quality implications. 
Requiring people co-infected with HIV 
and tuberculosis to stabilize on tuber-
culosis treatment before initiating ART 
may be beneficial only for patients with 
very low CD4 counts.97 Allowing certain 
sites to provide ART refills may also be 
advantageous, allowing patients to ac-
cess drugs nearer home. Fast-tracking 
patients into care (with rapid ART initia-
tion and no requirements for laboratory 
tests or adherence counselling) may in-
crease immediate uptake of services, but 
could undermine long-term adherence 
if patients are inadequately prepared for 
treatment. Not insisting on routine CD4 
monitoring of ART patients in Malawi 
forms an important aspect of the public 
health approach to scaling up access, 
but may have negative consequences for 
timely identification of treatment failure.
Our review has some limitations. 
First, establishing the precise date of policy 
enactment was challenging. Publication 
dates represent formal enactment, but key 
informants reported instances in which 
policies came into effect earlier. Certain 
policies did not reappear in more recent 
documents, casting doubt on their validity. 
Furthermore, countries that recently pro-
duced HIV guidelines (South Africa: 2013 
ART guidelines; Kenya: 2012 PMTCT 
guidelines) may appear to have more 
‘advanced’ policies than those currently 
in the process of updating their guide-
lines, including Malawi and the United 
Republic of Tanzania. Second, the extent 
to which all relevant policy indicators 
were captured is uncertain. Our systematic 
approach to develop tools and indicators 
attempted to minimize this, but there may 
be other factors that were missed. We 
did not investigate the broader national 
policy environment (Fig. 1). Factors such 
as national politics, laws and the criminal 
justice system, programme financing 
mechanisms and donor coordination have 
been shown to have strong influences on 
health seeking-behaviour and service 
response.98–101 Country-specific policy 
analyses will be needed to analyse these 
national influences in detail.
Interpreting these findings with 
regard to potential programme impact 
is challenging. In part this stems from 
the wide variation demonstrated in 
our analysis, but perhaps more im-
portantly because policies are only the 
first step in programme delivery. Their 
effectiveness depends on service-level 
implementation, as well community-
level factors.99,100, Further analysis will 
examine how these different policies 
are implemented in ALPHA’s network 
of health and demographic surveillance 
sites. This will allow us to assess whether 
policy translates into practice and 
whether practice exceeds stated policies, 
as often claimed by our key informants. 
International efforts to monitor policy 
implementation – such as WHO’s esti-
mates on ART policy implementation24 
– are increasing and we hope that this 
review and its tools can support other 
efforts to track national policies. ■
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صخلم
ةممعم ةئبوأ نم نياعت ةيقيرفأ نادلب ةتس في يشربلا يعانلما زوعلا سويرف ةحفاكم ةينطولا تاسايسلل نراقم ليلتح
 يعانلما زوعلا سويرف ةحفاكلم ةينطولا تاسايسلا ةنراقم :ضرغلا
 تامدخ نم ةدافتسلاا لىع ةردقلا لىع رثؤت يتلاو )HIV(يشربلا
 نادلب ةتس في يشربلا يعانلما زوعلا سويرف نم جلاعلاو رابتخلاا
.ءارحصلا بيونج ةعقاو ةيقيرفأ
 يعانلما  زوعلا  سويرف  ةحفاكم  تاسايس  انعجار  دقل  :ةقيرطلا
 لوح  نادلبلا  نم  ديدعلا  تلمش  ةـسارد  نم  ءزجك  يشربلا
 بيونج  ةعقاولا  ةيقيرفلأا  نادلبلا  في  ينغلابلا  تايفو  تلادعم
 ةعجارلم  ةسايسلا  صلاختسا  ةادأ  مادختساو دادعإ  مت  .ءارحصلا
 يعانلما زوعلا سويرف ةحفاكم ةسايسل ةيهيجوتلا ئدابلماو قئاثولا
 ايقيرفأ  بونجو  يولامو  اينيك  في  تشرن  يتلا  ةينطولا  يشربلا
 ينب  ام  ةترفلا  في  يوبابمزو  ةدحتلما  اينازنت  ةيروهجمو  ادنغوأو
 ينسيئرلا  ينغّلبلما  تلاباقم  تدعاس  دقلو  .2013و 2003 ماع
 اذإ الم اًقفو ةينطولا تاسايسلا تفِّنُص .جئاتنلا في تارغثلا دس لىع
 يتلا ،ةسايسلا تاشرؤم نم 54 ـب اًينمض وأ ًةحاصر تمزتلا تناك
 انمقو .ءابرلخا تاعجارمو ةيبطلا تافلؤلما للاخ نم اهديدتح مت
 ةحصلا  ةمظنم  تاهيجوت  عم  ةينطولا  تاسايسلا  ةنراقمب  اًضيأ
.)WHO( ةيلماعلا
 ثيح  ؛نادلبلا  ينب  تاسايسلا  في  يربك  توافت  كانه  ناك  :جئاتنلا
 يولام تناك .اهيرغ نود بناولجا ضعب في مدقتلاب دلب لك زيتم
 جلاعلا ءدب في عاسرلإا ةركف زيزعت في صوصلخا هجو لىع ةمدقتم
 نكي  لم  ،كلذ  عمو  .ةيرقهقلا  تاسويرفلا  تاداضم  مادختساب
 ةروصب  تاردقلا  ريوطت  حيتت  ةسايس  قيبطتل  قايس  دلب  يأ  ىدل
 دلحاو  ةياعرلا  نم  ةدافتسلاا  لبس  يرسيت  هنم  رظتنُي  ثيحب  ،ةتباث
 ةحصلا  ةمظنم  تاهيجوت  زواجتب  نادلبلا  تماق  .فازنتسلاا  نم
 اًبلاغ ةسرمالما  نأ  نوسيئرلا  نوغّلبلما  ركذو ةنيعم قطانم  في ةيلماعلا
.ةسايسلا زواجتت تناك ام
 صرف  في  ةسايسلا  تافلاتخا  يرثأت  مييقت  يرسعلا  نم  :جاتنتسلاا
 ينباصلما  صاخشلأا  ينب  ةيحصلا  جئاتنلاو  ةياعرلا  لىع  لوصلحا
 تاسايسلا  ضعب  ققتح  فوسف  .يشربلا  يعانلما  زوعلا  سويرفب
 تاسايسلا ذيفنت ًمائاد متي لا ماك ،اهاوس نود يرثأتلا نم ديزلما ةنيعلما
 ذيفنت  ىدم  مييقت  ةيلبقتسلما  ثاحبلأا  لىع  يغبني  .ةيمسرلا
 زوعلا  سويرفب  ةباصلإا  لئاصحب  جئاتنلا  هذه  طبرو  تاسايسلا
.يشربلا يعانلما
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摘要
在艾滋病病毒广泛流行的六个非洲国家中开展关于国家艾滋病病毒政策的对比分析
目的 旨在对比在撒哈拉沙漠以南的六个非洲国家中能
够影响艾滋病病毒测试和治疗服务的国家艾滋病病毒 
(HIV) 政策。
方法 在撒哈拉沙漠以南的非洲国家中进行有关成人死
亡率的多国研究期间 , 我们评审了艾滋病病毒政策。 当
时开发了一种政策提取工具并将其用于评审津巴布
韦、肯尼亚、马拉维、南非、坦桑尼亚联合共和国以
及乌干达在 2003 年和 2013 年期间出版的国家艾滋病
病毒政策文件和指南。关键知情人访谈帮助我们弥补
了调查结果中的不足之处。 我们依据国家政策是否以
明确或隐含的方式遵循 54 项政策指标来对其进行分
类 , 并且通过文献和专家评审加以确认。 同时 , 我们
还对比了国家政策和世界卫生组织 (WHO) 指南。
结果 各国的政策差异很大 ; 每个国家都在一些方面达
到先进水平 , 而在另一些方面却没有达到先进水平。 马
拉维在推动抗逆转录病毒疗法的快速启动方面尤为先
进。 然而 , 没有一个国家能够终保持一贯有利的政策
环境 , 难以按预期提高护理普及率和预防消耗。 各国
在某些方面超出了世界卫生组织指南的范围 , 并且据
关键知情人报告 , 实际情况往往超越政策范围。
结论 评估政策差异对艾滋病病毒患者的护理普及率和
医疗效果的影响具有挑战性。 某些政策会比其他政策
产生更大的影响 , 并且官方政策并不总是能够得到落
实。 今后的研究应评估政策实施的程度 , 并将这些调
查结果与艾滋病病毒的医疗效果联系起来。
Résumé
Analyse comparative des politiques nationales de lutte contre le VIH dans six pays africains où l’épidémie est généralisée
Objectif Comparer les politiques nationales de lutte contre le virus 
de l’immunodéficience humaine (VIH) qui influencent l’accès aux 
services de dépistage et de traitement du VIH dans six pays d’Afrique 
subsaharienne.
Méthodes Nous avons examiné les politiques de lutte contre le VIH dans 
le cadre d’une étude multi-pays sur la mortalité des adultes en Afrique 
subsaharienne. Un outil d’extraction de données a été mis au point et 
utilisé afin d’examiner les documents et les directives des politiques 
nationales de lutte contre le VIH publiés en Afrique du Sud, au Kenya, au 
Malawi, en Ouganda, en République-Unie de Tanzanie et au Zimbabwe 
entre 2003 et 2013. Des entretiens avec des informateurs clés ont permis 
de combler les carences de ces résultats. Les politiques nationales 
ont été classées suivant leur degré de correspondance, explicite ou 
implicite, avec 54 indicateurs relatifs aux politiques, déterminés d’après 
des analyses documentaires et des examens d’experts. Nous avons 
également comparé les politiques nationales avec les recommandations 
de l’Organisation mondiale de la Santé (OMS).
Résultats Nous avons observé de grandes différences entre les 
politiques de ces pays ; chaque pays était avancé dans certains domaines 
et pas dans d’autres. Le Malawi l’était particulièrement en matière de 
promotion du démarrage rapide du traitement antirétroviral. Cependant, 
aucun pays n’avait un contexte politique pouvant systématiquement 
permettre d’augmenter l’accès aux soins et d’éviter l’arrêt du 
traitement. Dans certains domaines, les pays allaient plus loin que les 
recommandations de l’OMS et les informateurs ont indiqué que la 
pratique dépassait souvent le cadre des politiques.
Conclusion Évaluer l’impact des différentes politiques sur l’accès aux 
soins et les résultats en termes de santé des personnes qui vivent avec 
le VIH n’est pas chose simple. Certaines politiques exercent une influence 
plus forte que d’autres et les politiques officielles ne sont pas toujours 
mises en œuvre. Des recherches ultérieures devraient évaluer le degré 
de mise en œuvre des politiques et mettre en lien leurs conclusions 
avec les résultats de la lutte contre le VIH.
Резюме
Сравнительный анализ государственной политики в отношении ВИЧ в шести странах Африки с 
генерализованной эпидемией
Цель Сравнить политику в отношении вируса иммунодефицита 
человека (ВИЧ) в шести странах Африки к югу от Сахары. 
Оценивается доступность анализа на ВИЧ и услуг по лечению.
Методы Политики в отношении ВИЧ были рассмотрены в рамках 
многонационального исследования смертности взрослого 
населения в странах Африки к югу от Сахары. Для анализа политик 
был разработан специальный инструмент, который использовался 
для проверки официальных документов и рекомендаций, 
связанных с государственной политикой в отношении ВИЧ, 
опубликованных в Кении, Малави, Южной Африке, Уганде, 
Объединенной Республике Танзания и Зимбабве в период между 
2003 и 2013 гг. Неясные моменты уточнялись благодаря ключевым 
информаторам. Национальные политики распределялись по 
категориям в зависимости от того, придерживались ли они 
явным или косвенным образом 54 показателей, выявленных в 
ходе оценки публикаций и отчетов специалистов. Было также 
проведено сравнение национальных политик с рекомендациями 
Всемирной организации здравоохранения (ВОЗ).
Результаты Политики в разных странах отличались друг от 
друга; в каждой из стран отмечался прогресс в одних областях и 
отставание в других. В частности, Малави значительно выделялась 
продвижением раннего начала антиретровирусной терапии. Тем 
не менее ни в одной стране не была реализована эффективная 
политика, которая облегчала бы доступ к медицинской 
помощи и препятствовала бы оттоку персонала. В некоторых 
областях страны пошли дальше рекомендаций ВОЗ и основные 
информаторы сообщили, что практика часто опережала политику.
Вывод Оценить, насколько отличия в государственной политике 
влияют на доступ к лечению и результаты мероприятий по охране 
здоровья для лиц, живущих с ВИЧ, довольно сложно. Некоторые 
из политик имеют сравнительно больший эффект, и официальная 
политика не всегда выполняется. В будущих исследованиях 
необходимо оценить степень выполнения политик и связать 
полученные данные с результатами лечения ВИЧ.
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Resumen
Un análisis comparativo de las políticas nacionales sobre el VIH en seis países africanos con epidemias generalizadas
Objetivo Comparar las políticas nacionales relativas al virus de la 
inmunodeficiencia humana (VIH) que influencian el acceso a las pruebas 
del VIH y a los tratamientos en seis países sub-saharianos.
Métodos Se revisaron las políticas relativas al VIH como parte de 
un estudio multinacional sobre la mortalidad de adultos en África 
Subsahariana. Se desarrolló una herramienta de extracción de políticas y 
se utilizó para revisar los documentos y guías de las políticas nacionales 
relativas al VIH publicadas en Kenia, Malawi, República Unida de Tanzania, 
Sudáfrica, Uganda y Zimbabue entre 2003 y 2013. Se hicieron entrevistas 
a informantes claves que ayudaron a llenar los vacíos en los resultados. 
Las políticas nacionales se clasificaron según si se adhirieron explícita 
o implícitamente a 54 indicadores de políticas, identificados mediante 
bibliografía y opiniones de expertos. Asimismo, se compararon las 
políticas nacionales con las directrices de la Organización Mundial de 
la Salud (OMS).
Resultados Se descubrió que había una amplia variedad entre las 
políticas de los países. Cada país estaba más avanzado en algunas áreas 
que en otras. Malawi estaba especialmente avanzado en la promoción 
de empezar rápidamente la terapia antirretroviral. Sin embargo, ningún 
país tenía un contexto de introducción de políticas consistente que 
incrementara el acceso a la atención primaria y evitara la deserción. 
Algunos países iban más allá de las orientaciones de la OMS en algunas 
áreas e informantes clave informaron de que la práctica a menudo 
superaba la política.
Conclusión Evaluar el impacto de las diferencias en las políticas relativas 
en el acceso a la atención primaria y los resultados en la salud entre 
aquellas personas con VIH es un reto. Algunas políticas ejercerán más 
influencia que otras y las políticas oficiales no siempre se aplican. Las 
investigaciones futuras deberían evaluar el grado de aplicación de las 
políticas y vincular estos resultados con los resultados del VIH.
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